Avizorex Pharma

AVX is a biopharmaceutical company dedicated to developing novel drugs that address significant ophthalmic medical needs. The company has completed a Phase 2a study of its lead candidate product, AVX-012, for patients with dry eye disease. The active ingredient in AVX-012 is a potent and selective agonist of the TRPM8 ion channel, a cold and osmotic sensor that regulates ocular surface hydration and blink frequency. TRPM8 agonists have demonstrated the potential to restore tear film stability and reduce discomfort in patients with dry eye disease.